Unknown

Dataset Information

0

Clinical Outcomes for Peripartum Cardiomyopathy in North America: Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy).


ABSTRACT: BACKGROUND:Peripartum cardiomyopathy (PPCM) remains a major cause of maternal morbidity and mortality. OBJECTIVES:This study sought to prospectively evaluate recovery of the left ventricular ejection fraction (LVEF) and clinical outcomes in the multicenter IPAC (Investigations of Pregnancy Associated Cardiomyopathy) study. METHODS:We enrolled and followed 100 women with PPCM through 1 year post-partum. The LVEF was assessed by echocardiography at baseline and at 2, 6, and 12 months post-partum. Survival free from major cardiovascular events (death, transplantation, or left ventricular [LV] assist device) was determined. Predictors of outcome, particularly race, parameters of LV dysfunction (LVEF), and remodeling (left ventricular end-diastolic diameter [LVEDD]) at presentation, were assessed by univariate and multivariate analyses. RESULTS:The cohort was 30% black, 65% white, 5% other; the mean patient age was 30 ± 6 years; and 88% were receiving beta-blockers and 81% angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. The LVEF at study entry was 0.35 ± 0.10, 0.51 ± 0.11 at 6 months, and 0.53 ± 0.10 at 12 months. By 1 year, 13% had experienced major events or had persistent severe cardiomyopathy with an LVEF <0.35, and 72% achieved an LVEF ?0.50. An initial LVEF <0.30 (p = 0.001), an LVEDD ?6.0 cm (p < 0.001), black race (p = 0.001), and presentation after 6 weeks post-partum (p = 0.02) were associated with a lower LVEF at 12 months. No subjects with both a baseline LVEF <0.30 and an LVEDD ?6.0 cm recovered by 1 year post-partum, whereas 91% with both a baseline LVEF ?0.30 and an LVEDD <6.0 cm recovered (p < 0.00001). CONCLUSIONS:In a prospective cohort with PPCM, most women recovered; however, 13% had major events or persistent severe cardiomyopathy. Black women had more LV dysfunction at presentation and at 6 and 12 months post-partum. Severe LV dysfunction and greater remodeling at study entry were associated with less recovery. (Investigations of Pregnancy Associated Cardiomyopathy [IPAC]; NCT01085955).

SUBMITTER: McNamara DM 

PROVIDER: S-EPMC5645077 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Clinical Outcomes for Peripartum Cardiomyopathy in North America: Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy).

McNamara Dennis M DM   Elkayam Uri U   Alharethi Rami R   Damp Julie J   Hsich Eileen E   Ewald Gregory G   Modi Kalgi K   Alexis Jeffrey D JD   Ramani Gautam V GV   Semigran Marc J MJ   Haythe Jennifer J   Markham David W DW   Marek Josef J   Gorcsan John J   Wu Wen-Chi WC   Lin Yan Y   Halder Indrani I   Pisarcik Jessica J   Cooper Leslie T LT   Fett James D JD  

Journal of the American College of Cardiology 20150801 8


<h4>Background</h4>Peripartum cardiomyopathy (PPCM) remains a major cause of maternal morbidity and mortality.<h4>Objectives</h4>This study sought to prospectively evaluate recovery of the left ventricular ejection fraction (LVEF) and clinical outcomes in the multicenter IPAC (Investigations of Pregnancy Associated Cardiomyopathy) study.<h4>Methods</h4>We enrolled and followed 100 women with PPCM through 1 year post-partum. The LVEF was assessed by echocardiography at baseline and at 2, 6, and 1  ...[more]

Similar Datasets

| S-EPMC4770544 | biostudies-literature
| S-EPMC4851559 | biostudies-literature
| S-EPMC6467571 | biostudies-literature
| S-EPMC5671863 | biostudies-other
| S-EPMC6382119 | biostudies-literature
| S-EPMC7083508 | biostudies-literature
| S-EPMC7846090 | biostudies-literature
| S-EPMC7754996 | biostudies-literature
| S-EPMC5815055 | biostudies-literature
| S-EPMC6132730 | biostudies-literature